Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech

Fauci: China's less-effective vaccines are stopping it from exiting COVID-zero

But a bigger problem for Beijing may be the number of elderly Chinese who have yet to get their booster shots.

Fortune

Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1

Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.

Reuters

Weekly Must-Read: Battle Begins for China’s Private Pension Funds

Institutions are rushing to bring investment products to market in wake of government plan to grow the underdeveloped sector

Caixin Global

From analysis to the latest developments in health,
read the most diverse news in one place.

European regulator recommends Pfizer's Omicron booster for children

Pfizer Inc and its partner BioNTech said on Thursday the EU health regulator has recommended authorising the use of their bivalent COVID-19 shot as a booster in children aged 5 through 11.

Reuters

BioNTech earnings drop but forecast for vaccine income grows

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported that third-quarter earnings are close to half what they were a year earlier

The Independent UK

Meta Goes Twitter Way With Layoffs, Twitter Might Want Some People Back After Firing Them, Coal Miners Terminate $6B Combination Discussions: Top Stories Monday, Nov. 07

Wall Street Journal

Benzinga

Pfizer, BioNTech start COVID-flu combination vaccine study

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.

Reuters

Read news from The Economist, FT, and more,
with one subscription

Pfizer starts early-stage trial of combined Covid and flu vaccine

The trial will look at the safety of the combined jab, how effective it is and whether patients suffer any side-effects

The Independent UK

Pfizer trying a jab which protects against flu and Covid

The drug is being tested on 180 people aged 18 to 64

Wales Online

Pfizer will start charging $110-$130 a dose for COVID vaccines next year

Price increases, while expected, could lead to higher insurance premiums.

Axios

Cancer vaccine being hailed by leading Covid scientists

The husband-and-wife duo who founded BioNTech has made a ‘breakthrough’ in the development of a cancer vaccine

Evening Standard

Cancer vaccine could be available by 2030 thanks to scientists behind Covid jab

The professors said that there was 'a number of breakthroughs' during the Covid vaccine development.

Daily Record

'Cancer vaccine' could be available in next 10 years as scientists behind vital jab raise hopes

German couple Professors Ugur Sahin and Ozlem Tureci said they are hesitant to say they can find a cure for cancer, but that they have had “breakthroughs” they will keep working on.

Irish Mirror

Covid vaccine lessons could 'accelerate cancer vaccine' in next 8 years

The founders of coronavirus jab manufacturers BioNTech say developing it gave back to their cancer work

Wales Online

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Vaccines to treat cancer possible by 2030, say BioNTech founders

Uğur Şahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells

Daily Mirror

Cancer vaccines will be available within 10 years thanks to Covid jabs, scientists say

Ugur Sahin and Ozlem Tureci, the founders of leading coronavirus vaccine makers BioNTech, have had significant “breakthroughs” in cancer research

The Independent UK

Cancer vaccine could be available by 2030, say scientists behind Covid jab

German couple Professors Ugur Sahin and Ozlem Tureci said they have had ‘breakthroughs’ they will keep working on.

Asharq Al-Awsat

Pfizer, BioNTech Find Updated COVID Booster Protects against Omicron in Trial

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up…

Get all your
news in one place.

100’s of premium titles.
One news app.

AAP

mRNA lab deal 'major coup' for Victoria

BioNTech has stuck an in-principle partnership with the Victorian government to establish an mRNA manufacturing facility in Melbourne.

The Guardian - UK

‘Like copying a Louis Vuitton handbag’: big pharma hits out at Africa’s replica Covid vaccine

Knowledge-sharing hub in Cape Town reverse engineered the Moderna vaccine, but future of the initiative to reduce inequity remains unsure

Benzinga

Check Out What Whales Are Doing With BNTX

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Reuters

Brazil approves Pfizer vaccine for children as young as six months

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Asharq Al-Awsat

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Evening Standard

Second Covid booster jab approved in UK ahead of winter vaccine programme

It’s the second jab aimed at both the original and Omicron strains of the virus, to be approved in the UK

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

76 stories

BNTX

63 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.